BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.51%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.85B
AUM Growth
+$9.85B
(-3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
226
New
13
Increased
56
Reduced
57
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$52.6M |
| 2 |
Revolution Medicines
RVMD
|
$44.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$37.4M |
| 4 |
Fate Therapeutics
FATE
|
$37M |
| 5 |
AMED
Amedisys
AMED
|
$36.1M |
Top Sells
| 1 |
Moderna
MRNA
|
$314M |
| 2 |
Halozyme
HALO
|
$53M |
| 3 |
Charles River Laboratories
CRL
|
$47.4M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$38M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$30.8M |
Sector Composition
| 1 | Healthcare | 96.84% |
| 2 | Industrials | 0.82% |
| 3 | Technology | 0.59% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HRC
51
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $63.1M | 0.64% |
420,716
-253,162
| -38% | -$38M |
|
52
Option Care Health
OPCH
$4.7B
| $63M | 0.64% |
2,595,814
+805,622
| +45% | +$19.5M |
|
53
Generation Bio
GBIO
$40.3M
| $62M | 0.63% |
2,472,180
-6,000
| -0.2% | -$150K |
|
54
Exelixis
EXEL
$9.95B
| $60.4M | 0.61% |
2,859,000
-73,000
| -2% | -$1.54M |
|
55
Omnicell
OMCL
$1.51B
| $58.4M | 0.59% |
393,583
| – | – |
|
56
Globus Medical
GMED
$7.94B
| $55.9M | 0.57% |
729,420
| – | – |
|
57
Penumbra
PEN
$10.5B
| $54.8M | 0.56% |
205,692
+23,567
| +13% | +$6.28M |
|
58
Esperion Therapeutics
ESPR
$490M
| $54.5M | 0.55% |
4,519,164
| – | – |
|
59
Beam Therapeutics
BEAM
$1.9B
| $53.3M | 0.54% |
612,821
| – | – |
|
|
VCRA
60
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $52.8M | 0.54% |
1,154,041
+501,209
| +77% | +$22.9M |
|
|
61
Sarepta Therapeutics
SRPT
$1.98B
| $52.6M | 0.53% |
+569,168
| New | +$52.6M |
|
62
Veeva Systems
VEEV
$44.4B
| $50.3M | 0.51% |
174,551
+1,904
| +1% | +$549K |
|
63
Thermo Fisher Scientific
TMO
$183B
| $49.6M | 0.5% |
86,879
+44,905
| +107% | +$25.7M |
|
|
ABMD
64
DELISTED
Abiomed Inc
ABMD
| $49.2M | 0.5% |
151,178
| – | – |
|
65
IQVIA
IQV
$31.4B
| $45.7M | 0.46% |
190,620
+13,220
| +7% | +$3.17M |
|
66
Molina Healthcare
MOH
$9.6B
| $45.6M | 0.46% |
168,255
-30,479
| -15% | -$8.27M |
|
|
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $45.6M | 0.46% |
416,200
-1,500
| -0.4% | -$164K |
|
68
Adaptive Biotechnologies
ADPT
$1.96B
| $45.4M | 0.46% |
1,336,023
+373,671
| +39% | +$12.7M |
|
|
AMED
69
DELISTED
Amedisys
AMED
| $45.1M | 0.46% |
302,798
+242,311
| +401% | +$36.1M |
|
70
Cigna
CI
$80.2B
| $43.6M | 0.44% |
217,812
-38,930
| -15% | -$7.79M |
|
|
SILK
71
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $43M | 0.44% |
781,660
-512,099
| -40% | -$28.2M |
|
72
Medtronic
MDT
$118B
| $42.5M | 0.43% |
339,125
-20,500
| -6% | -$2.57M |
|
73
Guardant Health
GH
$8.11B
| $42.5M | 0.43% |
339,894
-39,715
| -10% | -$4.96M |
|
74
Pacific Biosciences
PACB
$378M
| $42M | 0.43% |
1,643,159
| – | – |
|
75
Zimmer Biomet
ZBH
$20.8B
| $41M | 0.42% |
280,082
| – | – |
|